← SynDRA
MK-2206
SynDRA canonical compound SYN0021265 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | AKT1 |
|---|
| Mechanism of action | Akt inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- AKT1 INHIBITOR
- AKT2 INHIBITOR
- Serine/threonine-protein kinase AKT inhibitor
- AKT3 INHIBITOR
- AKT1 NEGATIVE ALLOSTERIC MODULATOR
- AKT2 NEGATIVE ALLOSTERIC MODULATOR
- AKT3 NEGATIVE ALLOSTERIC MODULATOR
- AKT3 MODULATOR
- UBE2T INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PIM1
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PCYT1A
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- OGG1
- NUAK2
- PHKG2
- PIP4K2A
- ABL1
- PIP4K2C
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- NTRK1
- NQO2
- NLK
- NEK9
Cross-references
Synonyms
- MK2206
- MK 2206
- UNII-51HZG6MP1K
- 51HZG6MP1K
- CHEMBL1079175
- CHEBI:67271
- NCGC00186465-01
- 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one
- DSSTox_RID_83143
- DSSTox_CID_28874
- 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one
- DSSTox_GSID_48948
- 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one
- 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;
- DTXCID0028874
- RefChem:553219
- 4HA45S22ZZ
- MK-2206 free base
- MK-2206 (free base)
- CAS-1032350-13-2
- SCHEMBL530721
- MK2206 2HCl
- GTPL7945
- orb1942981
- SCHEMBL2027678
- MK-2206 2HCl?
- ULDXWLCXEDXJGE-UHFFFAOYSA-N
- Tox21_113368
- BDBM50313650
- NSC756656
- NSC800794
- NSC839864
- AKOS032945686
- Tox21_113368_1
- NSC-756656
- NSC-800794
- NSC-839864
- SB16805
Look up MK-2206 in the interactive SynDRA portal →